Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by CARLI, P M
Right arrow Articles by LAVAULT, J F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by CARLI, P M
Right arrow Articles by LAVAULT, J F
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1989 Oxford University Press

research-article

Multiple Myeloma: Epidemiological Features in a Well-Defined Population in Burgundy, France

P M CARLI*, F BAILLY*, C TAVERNIER**, C MILAN{dagger}, D HEUDES* and J F LAVAULT**

*Registre des Hémopathies Malignes, Laboratoire d'Hématologie, 2 Bd de Lattre de Tassigny 21034 Dijon Cedex, France.
**Service de Rhumatologie Chu Dijon.
{dagger}Registre des Tumeurs Digestives Inserm SCN 17, Chu Dijon.

Carli P M (Registre des Hémopathies Malignes, Laboratoire d'Hématologie, 2 Bd de Lattre de Tassigny, 21034 Dijon, Cedex-France), Bailly F, Tavernier C, Milan C, Heudes D and Lavault J F. Multiple myelome: epidemiological features in a well-defined population in Burgundy, France. International Journal of Epidemiology 1989, 18: 330–333.

Epidemiological features of multiple myeloma were studied over a seven-year period (1980–86) in the department of Côte d'Or (population 478000). The crude annual incidence rates were 3.7/100000 for males and 4.0/100 000 for females. The corresponding age-standardized rates were 2.5 and 2.1. The sex ratio was 1.2. Cumulative rates were 0.3% for both sexes. Age and specific incidence were low before 50 and increased with advancing age up to 85 years in males and females. There was no significant variation in incidence over the seven-year period. The risk of multiple myeloma was slightly higher in urban than in rural areas (the variations were not significant). The period between the beginning of the symptoms and the diagnosis was often short, less than one month in 56% of the cases. When compared to other population based registries the incidence rates are similar to those reported all over the world (except for registries with a high proportion of blacks in the population). Cases have been staged according to Durie and Salmon classification: 32% of the cases were classified as Stage I. This result suggests that globally cases diagnosed in a well-defined population are less severe than those reported in hospital statistics. Survival showed significant differences: there were better rates for patients under 75 and for patients at stage I and II compared with stage III patients. Percentage and morphology of plasma cells also influenced prognosis.

Received 1 November 1988


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
L. Mileshkin, J. J. Biagi, P. Mitchell, C. Underhill, A. Grigg, R. Bell, J. McKendrick, P. Briggs, J. F. Seymour, K. Lillie, et al.
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age
Blood, July 1, 2003; 102(1): 69 - 77.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.